The National Human Genome Research Institute (NHGRI) Microarray Core (MAC) was established in 2000. The facility represents a consortium between NHGRI, the National Institute of Mental Health (NIMH) and the National Institute of Neurological Disorders and Stroke (NINDS). It has been providing intramural investigators with full service, cost-effective and time-efficient access to comprehensive state-of-the-art genomics and transcriptomics technologies for understanding genome copy number, patterns of gene expression, microRNA profiles and epigenetics.
Most investigator project requests are "full service", where the investigator will provide the chips, labeling kit and isolated RNA/DNA samples, and the core performs labeling, hybridization and data extraction. Upon project completion the investigator is then provided with a summary report including the data quality assessment, preliminary analysis and raw data output files. The core serves basic science, translational and clinical researchers and provides hands on training/education to investigators, postdoctoral fellows and students as well as consultation on experimental design.
Since its conception, the core has processed tens of thousands of RNA/DNA samples thus building experience and expertise in bringing accuracy and consistency to our genomics services through rigorous standardization of protocols and multiple quality control checks.
The core supports analysis on all major microarray platforms: Agilent, Affymetrix and Illumina to offer a broad range of products and services, including whole genome gene expression, genotyping (SNP), epigenetics (DNA methylation, histone status), copy number variation (CNV, LOH and CGH), non-coding and microRNA analysis as well as protein array profiling.
Dr. Abdel Elkahloun obtained his B.Sc. from the University of Caen, and a M.Sc. and Ph.D. from the University of Rennes, France. His Ph.D. thesis was on the positional cloning, physical mapping and genetics of hemochromatosis. He completed his first post-doctoral training under Dr. Paul Meltzer at the University of Michigan for the study of sarcomas and solid tumors and then joined the National Human Genome Research Institute (NHGRI) in 1993.
At the NHGRI, Dr. Elkahloun started applying large scale screening methods to identify genes associated with osteosarcomas and was part of the team that first developed the microarray technology at the NIH. In 1996, Dr. Elkahloun joined Research Genetics, Inc., where he started a microarray department to produce the first commercially available microarrays ("GeneFilters"). In 1999, Dr. Elkahloun joined the NHGRI to start the first microarray core facility at the National Institutes of Health.
Posted: December 13, 2016